Pedobarography as a clinical tool in the management of diabetic feet in New Zealand: a feasibility study

Background The peripheral complications of diabetes mellitus remain a significant risk to lower‐limb morbidity. In New Zealand, risk of diabetes, comorbidity and lower‐limb amputation are highly‐differential between demographic groups, particularly ethnicity. There is growing and convincing evidence that the use of pedobarography – or plantar pressure measurement – can usefully inform diabetic foot care, particularly with respect to the prevention of re‐ulceration among high‐risk patients. Methods For the current feasibility study, we embedded pedobarographic measurements into three unique diabetic foot clinic settings in the New Zealand context, and collected pedobarographic data from n = 38 patients with diabetes using a platform‐based (Novel Emed) and/or in‐shoe‐based system (Novel Pedar). Our aim was to assess the feasibility of incorporating pedobarographic testing into the clinical care of diabetic feet in New Zealand. Results and Conclusions We observed a high response rate and positive self‐reported experience from participants. As part of our engagement with participants, we observed a high degree of lower‐limb morbidity, including current ulceration and chronic foot deformities. The median time for pedobarographic testing (including study introduction and consenting) was 25 min. Despite working with a high‐risk population, there were no adverse events in this study. In terms of application of pedobarography as a clinical tool in the New Zealand context, the current feasibility study leads us to believe that there are two avenues that deserve further investigation: a) the use of pedobarography to inform the design and effectiveness of offloading devices among high‐risk diabetic patients; and b) the use of pedobarography as a means to increase offloading footwear and/or orthoses compliance among high‐risk diabetic patients. Both of these objectives deserve further examination in New Zealand via clinical trial.